The final report of the real-world evaluation of the WID®-easy test at University Hospitals Sussex NHS Foundation Trust is now available. It was prepared by Unity Insights in collaboration with Health Innovation Kent Surrey Sussex, University Hospitals Sussex NHS Foundation Trust as lead partner, the Office for Life Sciences and further NHS partners. The evaluation shows how the test performs in routine care and what a WID®-easy-led diagnostic pathway would mean for patients and costs.
Between August 2025 and February 2026, 487 women aged 45 and over attending urgent suspected cancer clinics with abnormal uterine bleeding received both the WID®-easy test and the standard diagnostic assessment, including transvaginal ultrasound (TVUS). Clinicians and patients were blinded to the WID®-easy result, and all patients continued on the standard pathway. Endometrial cancer was diagnosed in 26 women (5.3%).
How the two methods compared in detecting endometrial cancer:
- Sensitivity: 96.2% for the WID®-easy test, 100% for TVUS. The difference is not statistically significant.
- Specificity: 97.4% for the WID®-easy test, 27.3% for TVUS at the standard threshold of 4 mm endometrial thickness (p < 0.001).
- False-positive results: 12 instead of 327.
- Inconclusive or incomplete tests: 0.6% instead of 5.4%.
The report’s economic model estimates that a WID®-easy-led pathway would save around £233 per patient based on national NHS reference costs. In the evaluated group, it would have meant 138 fewer acute diagnostic procedures such as ultrasound scans, biopsies and hysteroscopies.
The authors also put the results into context: the evaluation was retrospective and observational, and the diagnosis of benign and pre-cancerous conditions such as hyperplasia depends on the design of the wider pathway. They recommend further interventional studies with longer-term follow-up to evaluate the management of women with a negative test result, assess long-term outcomes and confirm the savings.
Advanced Global Health Ltd, our distribution partner in the UK, supplied the WID®-easy testing service for the evaluation. The company remained blinded to individual patient results and had no role in data collection or analysis.
For Sola Diagnostics GmbH, the report adds data from routine NHS care to the published studies.
Click here for the full report (PDF, 34 pages): Real world evaluation of the WID-easy Test in secondary care